The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Treatment Guidelines for Helicobacter pylori Infection in Korea

헬리코박터 파일로리 감염의 진단 및 치료 가이드라인

Kim, Na-Young;Kim, Jae-J.;Choe, Yon-Ho;Kim, Hyun-Soo;Kim, Jin-Il;Chung, In-Sik
김나영;김재준;최연호;김현수;김진일;정인식

  • Published : 20091100
⟨ Previous Next ⟩

Abstract

Eleven years has passed since the guideline of the Korean College of Helicobacter and Upper Gastrointestinal Research group for H. pyori infection was produced in 1998. During this period the research for H. pyori has much progressed that H. pyori is now regarded as the major cause of gastric cancer. The seroprevalence of H. pyori in Korea was found to be decreased especially below the age of 40's and in the area of SeoulㆍGyeonggi province, and annual reinfection rate of H. pyori has decreased up to 2.94%. In the aspect of diagnostic tests of H. pyori the biopsy is recommended in the body instead of antrum in the subjects with atrophic gastritis and/or intestinal metaplasia for the modified Giemsa staining or Warthin Starry silver staining. The urea breath test is the test of choice to confirm eradication when follow-up endoscopy is not necessary. Definite indication for H. pyori eradication is early gastric cancer in addition to the previous indications of peptic ulcer including scar and Marginal zone B cell lymphoma (MALT type). Treatment is also recommended for the relatives of gastric cancer patient, unexplained iron deficiency anemia, and chronic idiopathic thrombocytopenic purpura. One or two week treatment of proton pump inhibitor (PPI) based triple therapy consisting of one PPI and two antibiotics, clarithromycin and amoxicillin, is recommended as the first line treatment regimen. In the case of treatment failure, one or two weeks of quadruple therapy (PPI＋metronidazole＋tetracycline＋bismuth) is recommended. Herein, Korean College of Helicobactor and Upper Gastrointestinal Research proposes a diagnostic and treatment guideline based on currently available evidence.

Keywords

References

  1. Korean Helicobacter pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275-289.
  2. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x
  3. Chung JI, Kim N, Kang KP, et al. Seroprevalence of Helicobacter pylori in the health check-up population in 2007. Korean J Helicobacter Upper Gastrointest Res 2008;8: 71-75.
  4. Kim JH, Kim HY, Kim N, et al. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001;16:969-975 https://doi.org/10.1046/j.1440-1746.2001.02568.x
  5. Kim N, Kim JG, Kim JH, et al. Risk factors of Helicobacter pylori infection in asymptomatic Korean population. Korean J Med 2000;59:376-387.
  6. Cheon JH, Kim N, Lee DH, et al. Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth containing quadruple therapy in Korea. Eur J Gastroenterol Hepatol 2006;18:515-519. https://doi.org/10.1097/00042737-200605000-00010
  7. Chung WC, Cho YS, Jeong JJ, et al. Eradication rate of Helicobacter pylori according to the disease and therapeutic regimens, and reinfection rate after successful eradication in a tertiary clinic. Korean J Gastroenterol 2003;41:1-8.
  8. Lee JH, Kim N, Jae Il Chung JI, et al. Long-term follow-up of Helicobacter pylori IgG serology after eradication and reinfection rate of Helicobacter pylori in South Korea. Helicobacter 2008;13:288-294. https://doi.org/10.1111/j.1523-5378.2008.00616.x
  9. Lee JH, Kim N, Jae Il Chung JI, et al. Long-term follow-up of Helicobacter pylori IgG serology after eradication and reinfection rate of Helicobacter pylori in South Korea. Helicobacter 2008;13:288-294. https://doi.org/10.1111/j.1523-5378.2008.00616.x
  10. Son JW, Han SY, Choi SY, Shin WW, Hong SH, Han JY. Comparison of simple diagnostic methods for Helicobacter pylori gastritis. Korean J Intern Med 1994;46:62-71.
  11. Lee WJ, Kim JG, Kim YT, et al. Evaluation of serological diagnosis for Helicobacter pylori infection. Korean J Gastroenterol 1994;26:631-636.
  12. Hong SP, Park HJ, Park IS, Lee KW, Kim HG. Serological diagnosis of Helicobacter pylori infection comparison of diagnostic values between HM-CAP (EPI) and GAP (Bio-Rad) test. Korean J Gastroenterol 1995;27:167-173.
  13. Kim SY, Ahn JS, Ha YJ, et al. Serodiagnosis of Helicobacter pylori infection in Korean patients using enzyme-linked immunosorbent assay. J Immunoassay 1998;19:251-270. https://doi.org/10.1080/01971529808005485
  14. Choe YH. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. Korean J Pediatr 2004;47:235-239.
  15. Choi KD, Yang HR, Seo JK, et al. Helicobacter pylori stool antigen test for the detection of Helicobacter pylori infection in children. J Korean Gastroenterol 2001;38:154-160.
  16. Yang HR, Seo JK. Role of enzyme immunoassay for the detection of Helicobacter pylori stool antigen in confirming eradication after quadruple therapy in children. Korean J Pediatric Gastroenterol Nutrit 2004;7:153-162.
  17. Yang HR, Seo JK. Helicobacter pylori stool antigen (HpSA) tests in children before and after eradication therapy: comparison of rapid immunochromatographic assay and HpSA ELISA. Dig Dis Sci 2008;53:2053-2058. https://doi.org/10.1007/s10620-007-0131-8
  18. Yoo JY, Kim N, Park YS, et al. Detection rate of Helicobacter pylori against a background of atrophic gastritis and/or intestinal metaplasia. J Clin Gastroenterol 2007;41:751-755. https://doi.org/10.1097/MCG.0b013e31802c347d
  19. Shin CM, Kim N, Lee HS, et al. Validation of diagnostic tests for Helicobacter pylori with regard to grade of atrophic gastritis and/or intestinal metaplasia. Helicobacter 2009;14: 512-519. https://doi.org/10.1111/j.1523-5378.2009.00726.x
  20. Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003;98:1005-1009. https://doi.org/10.1111/j.1572-0241.2003.07426.x
  21. Parente F, Sainaghi M, Sangaletti O, et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther 2002;16:553-557 https://doi.org/10.1046/j.1365-2036.2002.01192.x
  22. Kim JI, Kim SG, Kim N, et al. Changing prevalence of upper gastrointestinal disease in 28,893 Koreans from 1995 to 2005. Euro J Gastroenterol Hepatol 2009;21:787-793. https://doi.org/10.1097/MEG.0b013e32830e285a
  23. Sander JO, Zanten VV, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Canadian Med Assoc J 1997;156:1565-1574.
  24. World Health Organization. LARC monographs on the evaluation of carcinogenic risk to human. Lyon, 1994;61:177.
  25. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epid Bio Prev 1997;6:639-643.
  26. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789. https://doi.org/10.1056/NEJMoa001999
  27. Matsukura N, Tajiri T, Kato S, Togashi A, Masuda G, Fujita I. Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric Cancer 2003;6:100-107.
  28. Zanghieri G, DiGregori C, Sacchetti C, et al. Familial occurrence of gastric cancer in the 2-year experience of a population- based registry. Cancer 1990;66:2047-2451 https://doi.org/10.1002/1097-0142(19901101)66:9<2047::AID-CNCR2820660934>3.0.CO;2-G
  29. Chang YW, Han YS, Lee DK, et al. Role of Helicobactor pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer 2002;101:469-474. https://doi.org/10.1002/ijc.10637
  30. Leung WK, Ng EK, Lam CC, et al. Helicobacter pylori infection in 1st degree relatives of Chinese gastric cancer patients. Scand J Gastroenterol 2006;41:274-279. https://doi.org/10.1080/00365520510024269
  31. Foschi R, Lucenteforte E, Bosetti C, et al. Family history of cancer and stomach cancer risk. Int J Cancer 2006;123:1429-1432. https://doi.org/10.1002/ijc.23688
  32. Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994;3:15-18.
  33. Shin CM, Kim N, Yang HJ, et al. Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer. J Clin Gastroenterol 2009 in press.
  34. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985;35:173-177. https://doi.org/10.1002/ijc.2910350206
  35. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow-up. J Clin Gastroenterol 2008;42:448-454. https://doi.org/10.1097/MCG.0b013e318046eac3
  36. Kim N, Park YS, Cho SI, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13:245-255. https://doi.org/10.1111/j.1523-5378.2008.00604.x
  37. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  38. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia inpatients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001; 134:380-386. https://doi.org/10.1001/archinte.134.2.380
  39. Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007;12 (suppl 2):S32-S38. https://doi.org/10.1111/j.1523-5378.2007.00563.x
  40. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16:1249-1259. https://doi.org/10.1046/j.1365-2036.2002.01301.x
  41. Kang JM, Kim N, Yoo JY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter 2008;13:146-156. https://doi.org/10.1111/j.1523-5378.2008.00592.x
  42. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane database Sys Rev 2006;(2):CD002096.
  43. Ford AC, Forman D, Bailey AG, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005;129:1910-1917. https://doi.org/10.1053/j.gastro.2005.09.016
  44. Rauws EA, Tytgat GN. Helicobacter pylori, gastritis and nonsteroidal drugs. Current Opinion Gastroenterol 1997;13:40-42. https://doi.org/10.1097/00001574-199703000-00017
  45. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21:1411-1418. https://doi.org/10.1111/j.1365-2036.2005.02444.x
  46. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;18:1018-1022.
  47. Freston JW. Long-term acid control and proton pump inhibitors: interaction and safety issues in perspective. Am J Gastroenterol 1997;92:51S-57S.
  48. Chey WD, Wong BCY. American College of Gastroenterol ogy Guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825. https://doi.org/10.1111/j.1572-0241.2007.01393.x
  49. Choe YH, Kwon YS, Jung MK, Kang SK, Hwang TS, Hong YC. Helicobacter pylori-associated iron-deficiency anemia in adolescent female athletes. J Pediatr 2001;139:100-104. https://doi.org/10.1067/mpd.2001.114700
  50. Choe YH, Kim SK, Hong YC. The relationship between Helicobacter pylori infection and iron-deficiency: seroprevalence study in 937 pubescent children. Arch Dis Child 2003; 88:178. https://doi.org/10.1136/adc.88.2.178
  51. Choe YH, Kim SK, Son BK, Lee DH, Hong YC, Pai SH. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999;4:135-139. https://doi.org/10.1046/j.1523-5378.1999.98066.x
  52. Dubois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005;100:453-459. https://doi.org/10.1111/j.1572-0241.2005.30252.x
  53. Malfertheiner P, Megraud F, O'morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 1999;45(suppl 1):S136-S139.
  54. Suzuki T, Matsushima M, Masui A, et al. Effect of Helicabacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005;100:1265-1270. https://doi.org/10.1111/j.1572-0241.2005.41641.x
  55. Hayashi H, Okuda M, Aoyagi N, et al. Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int 205;47:292-295. https://doi.org/10.1111/j.1442-200x.2005.02058.x
  56. Franchini M. Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection. Med Hypotheses 2005;65:1128-1131. https://doi.org/10.1016/j.mehy.2005.06.015
  57. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 15-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004;48:4843-4847. https://doi.org/10.1128/AAC.48.12.4843-4847.2004
  58. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-35. https://doi.org/10.1111/j.1523-5378.2007.00538.x
  59. Kim N, Park SH, Seo GS, et al. Lafutidine vs. lansoprazole in combination with clarithromycin and amoxicillin for 1 vs. 2 week for Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542-549. https://doi.org/10.1111/j.1523-5378.2008.00648.x
  60. Park MJ, Choi IJ, Kim JS, et al. Efficacy of quadruple therapy as retreatment regimen in Helicobacter pylori-positive peptic ulcer disease. Korean J Gastroenterol 2000;36:457-464.
  61. Lee BH, Kim N, Hwang TJ, et al, Quadruple therapy as second- line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter in press.
  62. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;48:19-24.
  63. Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;47:30-36.
  64. Cheon JH, Kim N, Lee DH, et al. Trial of Moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J Gastroenterol 2005;45:111-117.
  65. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication. Helicobacter 2009;14:77-85.
  66. Perri F, Festa V, Clemente R, et al. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.

Cited by

  1. A Comparison Analysis on the Diagnosis of Helicobacter pylori Infection and the Detection of Clarithromycin Resistance according to Biopsy Sites vol.30, pp.4, 2009, https://doi.org/10.3343/kjlm.2010.30.4.381
  2. Extragastric Manifestations of Helicobacter pylori Infection vol.15, pp.suppl1, 2009, https://doi.org/10.1111/j.1523-5378.2010.00778.x
  3. Antibiotics-associated Diarrhea and Other Gastrointestinal Abnormal Responses RegardingHelicobacter pyloriEradication vol.56, pp.4, 2010, https://doi.org/10.4166/kjg.2010.56.4.229
  4. Randomised clinical trial: the efficacy of a 10‐day sequential therapy vs. a 14‐day standard proton pump inhibitor‐based triple therapy for Helicobacter pylori in Korea vol.34, pp.9, 2009, https://doi.org/10.1111/j.1365-2036.2011.04843.x
  5. Mutations of Helicobacter pylori Associated with Fluoroquinolone Resistance in Korea vol.16, pp.4, 2011, https://doi.org/10.1111/j.1523-5378.2011.00840.x
  6. Second‐line Helicobacter pylori Eradication: A Randomized Comparison of 1‐week or 2‐week Bismuth‐containing Quadruple Therapy vol.16, pp.4, 2009, https://doi.org/10.1111/j.1523-5378.2011.00844.x
  7. Helicobacter pyloriEradication Therapy in Korea vol.58, pp.2, 2011, https://doi.org/10.4166/kjg.2011.58.2.67
  8. Primary Antibiotic Resistance ofHelicobacter pyloriStrains and Eradication Rate according to Gastroduodenal Disease in Korea vol.58, pp.2, 2011, https://doi.org/10.4166/kjg.2011.58.2.74
  9. The Usefulness of the Regular Arrangement of Collecting Venules Pattern for the Determination ofHelicobacter pyloriInfection vol.58, pp.5, 2009, https://doi.org/10.4166/kjg.2011.58.5.252
  10. Organic Upper Digestive Diseases in Children with Chronic Abdominal Pain vol.14, pp.3, 2011, https://doi.org/10.5223/kjpgn.2011.14.3.232
  11. Effect of Acid Pump Antagonist (Revaprazan, Revanex®) on the Result of13C Urea Breath Test in the Patients withHelicobacter pyloriAssociated Peptic Ulcer Disease vol.57, pp.1, 2009, https://doi.org/10.4166/kjg.2011.57.1.1
  12. 안중산 투여 후 증상호전을 보인 급성 소화성 궤양 환자 1례 증례보고 vol.19, pp.1, 2009, https://doi.org/10.14374/hfs.2011.19.1.253
  13. Sequential Therapy ofHelicobacter pyloriInfection vol.11, pp.2, 2011, https://doi.org/10.7704/kjhugr.2011.11.2.103
  14. Treatment and Prognosis of Gastric MALT Lymphoma vol.11, pp.3, 2009, https://doi.org/10.7704/kjhugr.2011.11.3.165
  15. IsHelicobacter pyloriEradication Effective in Managing Functional Dyspepsia? vol.59, pp.2, 2009, https://doi.org/10.4166/kjg.2012.59.2.200
  16. Comparison of Rifabutin- and Levofloxacin-based Third-line Rescue Therapies forHelicobacter pylori vol.59, pp.6, 2012, https://doi.org/10.4166/kjg.2012.59.6.401
  17. Comparison of the Antibiotic Resistance of Helicobacter pylori Isolated in Jinju Over a 15-year Period vol.42, pp.4, 2009, https://doi.org/10.4167/jbv.2012.42.4.305
  18. Cancer Screening Status in Korea, 2011: Results from the Korean National Cancer Screening Survey vol.13, pp.4, 2009, https://doi.org/10.7314/apjcp.2012.13.4.1187
  19. Benign regional lymph nodes in gastric cancer on multidetector row CT vol.53, pp.5, 2009, https://doi.org/10.1258/ar.2012.120054
  20. Recent Trends ofHelicobacter pyloriEradication Therapy in Korea vol.12, pp.4, 2009, https://doi.org/10.7704/kjhugr.2012.12.4.219
  21. Future ofHelicobacter pyloriEradication-New Trials vol.12, pp.4, 2012, https://doi.org/10.7704/kjhugr.2012.12.4.232
  22. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy vol.13, pp.None, 2009, https://doi.org/10.1186/1471-230x-13-138
  23. Comparative Study of Helicobacter pylori Eradication Rates With 5-day Quadruple “Concomitant” Therapy and 7-day Standard Triple Therapy vol.47, pp.1, 2013, https://doi.org/10.1097/mcg.0b013e3182548ad4
  24. Helicobacter pyloriand Hematologic Diseases vol.84, pp.6, 2009, https://doi.org/10.3904/kjm.2013.84.6.769
  25. Guidelines for the Diagnosis and Treatment ofHelicobacter pyloriInfection in Korea, 2013 Revised Edition vol.62, pp.1, 2009, https://doi.org/10.4166/kjg.2013.62.1.3
  26. Eradication of Helicobacter pylori According to 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance vol.208, pp.7, 2013, https://doi.org/10.1093/infdis/jit287
  27. Meta-analysis: Sequential Therapy Is Superior to Conventional Therapy forHelicobacter pyloriInfection in Korea vol.62, pp.5, 2009, https://doi.org/10.4166/kjg.2013.62.5.267
  28. Hematologic manifestations ofHelicobacter pyloriinfection vol.20, pp.36, 2014, https://doi.org/10.3748/wjg.v20.i36.12818
  29. Trends in the Eradication Rates ofHelicobacter pyloriInfection in Daegu and Gyeongsangbuk-do, Korea: Multicenter Study over 13 Years vol.63, pp.2, 2009, https://doi.org/10.4166/kjg.2014.63.2.82
  30. Changes in the Antibiotic Resistance Rates ofHelicobacter pyloriStrains Isolated in Tertiary Medical Institutions in Seoul vol.86, pp.3, 2014, https://doi.org/10.3904/kjm.2014.86.3.308
  31. New Therapeutic Strategies againstHelicobacter pylori vol.63, pp.3, 2009, https://doi.org/10.4166/kjg.2014.63.3.146
  32. New Guidelines forHelicobacter pyloriTreatment: Comparisons between Korea and Japan vol.63, pp.3, 2009, https://doi.org/10.4166/kjg.2014.63.3.151
  33. Future Trends ofHelicobacter pyloriEradication Therapy in Korea vol.63, pp.3, 2009, https://doi.org/10.4166/kjg.2014.63.3.158
  34. Successful Eradication ofHelicobacter pyloriUsing Modified Quadruple Therapy in Patient with Long-lastingH. pylori-induced Active Gastritis vol.14, pp.1, 2014, https://doi.org/10.7704/kjhugr.2014.14.1.52
  35. Recent Trends ofHelicobacter pyloriEradication Therapy: Focusing on First Line Treatment vol.14, pp.4, 2009, https://doi.org/10.7704/kjhugr.2014.14.4.237
  36. Fourteen-vsseven-day bismuth-based quadruple therapy for second-lineHelicobacter pylorieradication vol.21, pp.26, 2009, https://doi.org/10.3748/wjg.v21.i26.8132
  37. The Effects of Broccoli Sprout Extract Containing Sulforaphane on Lipid Peroxidation and Helicobacter pylori Infection in the Gastric Mucosa vol.9, pp.4, 2009, https://doi.org/10.5009/gnl14040
  38. Concomitant therapy achieved the best eradication rate forHelicobacter pyloriamong various treatment strategies vol.21, pp.1, 2009, https://doi.org/10.3748/wjg.v21.i1.351
  39. Annual Eradication Rates ofHelicobacter pyloriInfection over 9 Years in Incheon vol.15, pp.2, 2009, https://doi.org/10.7704/kjhugr.2015.15.2.103
  40. Ten Years Retrospective Study aboutHelicobacter pyloriEradication Rate vol.15, pp.2, 2009, https://doi.org/10.7704/kjhugr.2015.15.2.112
  41. Web Survey of Society Members' Recognition of Guidelines for the Diagnosis and Treatment ofHelicobacter pyloriInfection in Korea, 2013 Revised Edition vol.15, pp.2, 2009, https://doi.org/10.7704/kjhugr.2015.15.2.95
  42. Diagnosis and Treatment of Helicobacter Pylori Infection vol.89, pp.2, 2009, https://doi.org/10.3904/kjm.2015.89.2.149
  43. Diagnosis and Treatment of Helicobacter Pylori Infection: Korean and Overseas Guidelines vol.89, pp.2, 2015, https://doi.org/10.3904/kjm.2015.89.2.157
  44. Eradication Rates of First-line and Second-line Therapy forHelicobacter pyloriInfection in Gyeongnam Province vol.15, pp.3, 2009, https://doi.org/10.7704/kjhugr.2015.15.3.160
  45. Historical Perspective ofHelicobacter pyloriTreatment in Korea vol.15, pp.4, 2015, https://doi.org/10.7704/kjhugr.2015.15.4.211
  46. Current Strategies for Eradication ofHelicobacter pyloriin Korea vol.15, pp.4, 2015, https://doi.org/10.7704/kjhugr.2015.15.4.222
  47. The Effects of Helicobacter pylori Eradication Therapy for Chronic Idiopathic Thrombocytopenic Purpura vol.10, pp.3, 2009, https://doi.org/10.5009/gnl14483
  48. The first-line regimens of Helicobacter pylori eradication in Korea vol.37, pp.1, 2017, https://doi.org/10.7599/hmr.2017.37.1.2
  49. Eradication Therapy for PediatricHelicobacter pyloriInfection vol.17, pp.1, 2009, https://doi.org/10.7704/kjhugr.2017.17.1.16
  50. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication vol.17, pp.None, 2009, https://doi.org/10.1186/s12876-017-0579-8
  51. Pharmacokinetic drug interaction and safety after coadministration of clarithromycin, amoxicillin, and ilaprazole: a randomised, open-label, one-way crossover, two parallel sequences study vol.74, pp.9, 2018, https://doi.org/10.1007/s00228-018-2489-2
  52. Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis vol.71, pp.1, 2018, https://doi.org/10.4166/kjg.2018.71.1.31
  53. The Efficacy of Rebamipide or Ecabet Sodium Supplementation for Helicobacter pylori Eradication Therapy Compared with Quadruple (Concomitant) Regimen vol.71, pp.4, 2009, https://doi.org/10.4166/kjg.2018.71.4.204
  54. New Helicobacter pylori Eradication Therapies vol.72, pp.5, 2018, https://doi.org/10.4166/kjg.2018.72.5.237
  55. Change in the Prevalences and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in Korea: Multicenter Clinical Trials vol.18, pp.4, 2018, https://doi.org/10.7704/kjhugr.2018.18.4.247
  56. First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study vol.18, pp.2, 2018, https://doi.org/10.7704/kjhugr.2018.18.2.120
  57. Trends in the seroprevalence of Helicobacter pylori infection and its putative eradication rate over 18 years in Korea: A cross-sectional nationwide multicenter study vol.13, pp.10, 2009, https://doi.org/10.1371/journal.pone.0204762
  58. Peptide Nucleic Acid Probe-Based Analysis as a New Detection Method for Clarithromycin Resistance in Helicobacter pylori vol.12, pp.6, 2009, https://doi.org/10.5009/gnl18111
  59. Eradication Rates of 10-day Sequential Therapy for Helicobacter pylori: Results of an 8-year Prospective Study Conducted at a Tertiary Korean Hospital vol.73, pp.2, 2009, https://doi.org/10.4166/kjg.2019.73.2.99
  60. The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population vol.24, pp.3, 2009, https://doi.org/10.1111/hel.12579
  61. Could Helicobacter pylori Treatment Reduce the Risk of Gastric Cancer in Individuals with a Family History of the Disease? vol.20, pp.2, 2020, https://doi.org/10.7704/kjhugr.2020.0016
  62. The Current Strategy of Helicobacter pylori Eradication vol.96, pp.1, 2009, https://doi.org/10.3904/kjm.2021.96.1.13
  63. Population Attributable Fraction of Helicobacter pylori Infection-Related Gastric Cancer in Korea: A Meta-Analysis vol.53, pp.3, 2009, https://doi.org/10.4143/crt.2020.610
  64. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: vol.21, pp.1, 2021, https://doi.org/10.1186/s12876-021-01680-1